genentech
Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M
Repertoire, genentech, Autoimmune Diseases, Immune Medicines, Partnership
FDA Approves Evrysdi Tablets: A Breakthrough in Convenient SMA Treatment
Evrysdi, risdiplam, spinal muscular atrophy (SMA), FDA approval, tablet formulation, oral treatment, Genentech, Roche
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
Roche Invests $850 Million in Regor’s Next-Generation CDK Inhibitors for Breast Cancer Treatment
Roche, Regor Pharmaceuticals, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition
Roche Acquires Regor’s CDK Inhibitors for $850M to Enhance Breast Cancer Portfolio
Roche, Regor Therapeutics, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition, transformative medicines
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
Genentech Announces 93 Layoffs in California Following Closure of Cancer Immunology Research Unit
Genentech, layoffs, California, cancer immunology research unit, biotech, workforce reduction
Genentech Closes Cancer Immunology Unit as Part of Broader R&D Restructuring
Genentech, Cancer Immunology, R&D Reprioritization, Roche, Cancer Research, Molecular Oncology
Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech
Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease